Bon Trinh, Ph.D.

Bon Trinh, Ph.D.
Assistant Professor of Pathology

Education and Training:

2002, B.S. Biotechnology, Vietnam National University, Hanoi, Vietnam
2011, Ph.D. Biomedical Sciences, University of Texas Graduate School of Biomedical Sciences, Houston, TX
2011-2016, Postdoctoral Fellow, Systems Biology, Molecular and Cellular Oncology, University of Texas MD Anderson Cancer, Houston, TX
2016-2020 Research Fellow in Medicine, Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
2020-2022 Instructor in Medicine, Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA


Myeloid cells, including granulocytes and macrophages, play a crucial role in the body’s de­fense against infections. Abnormalities in their functions and maturation cause various diseases. At the Trinh laboratory, we employ experimental and computational approaches to understand how proteins and RNAs act at chromatin level to control activities of key genes involved in normal myeloid cell maturation, leukemia development, myeloid cell – cancer cell communication in the tumor microenvironment, as well as drug response. The aims are to identify actionable molecular targets and diagnostic biomarkers, and to develop innovative therapeutic strate­gies for diseases such as cancer. Learn more

Selected Publications:

  • Trinh BQ*, Ummarino S, Zhang Y, Ebralidze AK, Bassal MA, Nguyen TM, Heller G, Coffey R, Tenen DE, van der Kouwe E, Fabiani E, Gurnari C, Wu CS, Angarica VE, Yang H, Chen S, Zhang H, Thurm AR, Marchi F, Levantini E, Staber PB, Zhang P, Voso TM, Pandolfi PP, Kobayashi SS, Chai L, Di Ruscio A & Tenen DG*. Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood Journal. 2021. PMID: 33971010 (*corresponding authors).
  • van der Kouwe E, Heller G, Czibere A, Agreiter C, Castilla LH, Delwel R, Di Ruscio A, Ebralidze AK, Forte M, Grebien F, Heyes E, Kazianka L, Klinger J, Kornauth C, Le T, Lind K, Barbosa MA, Pemovska T, Pichler A, Pulikkan JA, Schmolke AS, Schweicker C, Sill H, Sperr W, Spittler A, Surapally S, Trinh BQ, Valent P, Vanura K, Welner RS, Zuber J, Tenen DG, Staber BP. Core binding factor leukemias hijack T-cell prone PU.1 antisense promoter. Blood Journal. 2021. PMID: 34010414.
  • Umarino S, Hausman C, Gaggi G, Rinaldi L, Bassal MA, Zhang Y, Seelam AJ, Kobayashi IS, Borchiellini M, Ebralidze AK, Ghinassi B, Trinh BQ, Kobayashi SS, Di Ruscio A. NAD modulates DNA methylation and cell differentiation. Cells. 2021. MDPI
  • Trinh BQ, Barengo N, Kim SB, Lee JS, Naora H. The homeobox gene DLX4 regulates erythro-megakaryocytic differentiation by stimulating IL-1b and NF-kB signaling. Journal of Cell Science 128(16):3055-67. 2015. PMID: 26208636
  • Trinh BQ, Ko SY, Haria D, Barengo N, & Naora H. The homeoprotein DLX4 controls ovarian tumor angiogenesis by regulating expression of inducible nitric oxide synthase. Molecular Cancer. Apr 30;14(1):97. 2015. PMID: 25924901
  • Haria D*, Trinh BQ*, Ko SY, Barengo N, Liu JS & Naora H. The homeoprotein DLX4 stimulates NF-κB activation and CD44-mediated tumor-mesothelial cell interactions in ovarian cancer. American Journal of Pathology 185(8):2298-308. 2015. PMID: 26067154 (*equal contribution)
  • Trinh BQ, Ko SY, Barengo N, Lin SY, Naora H. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs. Cancer Research 73:1000-10. 2013. PMID: 23222298
  • Trinh BQ, Naora H. Homeobox genes and theirs functional significance in ovarian tumorigenesis, Ovarian Cancer / Book 1, ISBN 978-953-307-812-0, 2012
  • Trinh BQ, Barengo N, Naora H. Homeodomain protein DLX4 counteracts key transcriptional control mechanisms of the TGF-b cytostatic program and blocks the anti-proliferative effect of TGF-b. Oncogene 30: 2718-2729. 2011. PMID: 21297662
  • Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC Jr, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics Aug;8(8):2375-82. 2009. PMID: 19671744